X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN LTD AJANTA PHARMA/
LUPIN LTD
 
P/E (TTM) x 20.0 16.6 120.0% View Chart
P/BV x 8.6 3.9 222.7% View Chart
Dividend Yield % 0.7 0.8 87.5%  

Financials

 AJANTA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
LUPIN LTD
Mar-16
AJANTA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,7202,127 80.9%   
Low Rs1,1031,294 85.2%   
Sales per share (Unadj.) Rs194.6304.1 64.0%  
Earnings per share (Unadj.) Rs45.250.4 89.7%  
Cash flow per share (Unadj.) Rs50.360.7 82.9%  
Dividends per share (Unadj.) Rs8.007.50 106.7%  
Dividend yield (eoy) %0.60.4 129.3%  
Book value per share (Unadj.) Rs132.0243.8 54.2%  
Shares outstanding (eoy) m88.77450.58 19.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.35.6 128.9%   
Avg P/E ratio x31.233.9 92.0%  
P/CF ratio (eoy) x28.128.2 99.6%  
Price / Book Value ratio x10.77.0 152.4%  
Dividend payout %17.714.9 118.9%   
Avg Mkt Cap Rs m125,299770,740 16.3%   
No. of employees `000NA16.4 0.0%   
Total wages/salary Rs m2,57021,077 12.2%   
Avg. sales/employee Rs ThNM8,379.6-  
Avg. wages/employee Rs ThNM1,289.0-  
Avg. net profit/employee Rs ThNM1,388.7-  
INCOME DATA
Net Sales Rs m17,275137,016 12.6%  
Other income Rs m1661,877 8.9%   
Total revenues Rs m17,442138,893 12.6%   
Gross profit Rs m5,80737,535 15.5%  
Depreciation Rs m4514,635 9.7%   
Interest Rs m49446 11.0%   
Profit before tax Rs m5,47434,330 15.9%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,46011,536 12.7%   
Profit after tax Rs m4,01422,707 17.7%  
Gross profit margin %33.627.4 122.7%  
Effective tax rate %26.733.6 79.4%   
Net profit margin %23.216.6 140.2%  
BALANCE SHEET DATA
Current assets Rs m7,63997,790 7.8%   
Current liabilities Rs m2,71553,872 5.0%   
Net working cap to sales %28.532.1 88.9%  
Current ratio x2.81.8 155.0%  
Inventory Days Days4385 51.0%  
Debtors Days Days79121 64.9%  
Net fixed assets Rs m6,91486,379 8.0%   
Share capital Rs m177901 19.6%   
"Free" reserves Rs m11,442105,735 10.8%   
Net worth Rs m11,721109,844 10.7%   
Long term debt Rs m14953,739 0.3%   
Total assets Rs m14,814224,378 6.6%  
Interest coverage x112.977.9 144.9%   
Debt to equity ratio x00.5 2.6%  
Sales to assets ratio x1.20.6 191.0%   
Return on assets %27.410.3 265.8%  
Return on equity %34.220.7 165.7%  
Return on capital %46.521.2 219.4%  
Exports to sales %55.149.1 112.4%   
Imports to sales %6.07.4 80.7%   
Exports (fob) Rs m9,52767,244 14.2%   
Imports (cif) Rs m1,03810,199 10.2%   
Fx inflow Rs m10,42271,405 14.6%   
Fx outflow Rs m1,67817,807 9.4%   
Net fx Rs m8,74453,598 16.3%   
CASH FLOW
From Operations Rs m3,264-3,690 -88.5%  
From Investments Rs m-2,093-69,434 3.0%  
From Financial Activity Rs m-1,18658,126 -2.0%  
Net Cashflow Rs m-15-14,998 0.1%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS